These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14980780)

  • 1. Targeted delivery of antisense oligodeoxynucleotides to folate receptor-overexpressing tumor cells.
    Yang L; Li J; Zhou W; Yuan X; Li S
    J Control Release; 2004 Mar; 95(2):321-31. PubMed ID: 14980780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes.
    Chiu SJ; Marcucci G; Lee RJ
    Anticancer Res; 2006; 26(2A):1049-56. PubMed ID: 16619505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate receptor targeted delivery of polyelectrolyte complex micelles prepared from ODN-PEG-folate conjugate and cationic lipids.
    Kim SH; Jeong JH; Mok H; Lee SH; Kim SW; Park TG
    Biotechnol Prog; 2007; 23(1):232-7. PubMed ID: 17269693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor.
    Zhao XB; Lee RJ
    Adv Drug Deliv Rev; 2004 Apr; 56(8):1193-204. PubMed ID: 15094215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles.
    Zhou W; Yuan X; Wilson A; Yang L; Mokotoff M; Pitt B; Li S
    Bioconjug Chem; 2002; 13(6):1220-5. PubMed ID: 12440856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of oligodeoxynucleotides to mouse lung endothelial cells in vitro and in vivo.
    Wilson A; Zhou W; Champion HC; Alber S; Tang ZL; Kennel S; Watkins S; Huang L; Pitt B; Li S
    Mol Ther; 2005 Sep; 12(3):510-8. PubMed ID: 15953766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD; Huang L
    Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
    Leamon CP; Cooper SR; Hardee GE
    Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate-mediated tumor cell uptake of quantum dots entrapped in lipid nanoparticles.
    Schroeder JE; Shweky I; Shmeeda H; Banin U; Gabizon A
    J Control Release; 2007 Dec; 124(1-2):28-34. PubMed ID: 17928088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved formulations of antisense oligodeoxynucleotides using wrapped liposomes.
    Yamauchi M; Kusano H; Saito E; Iwata T; Nakakura M; Kato Y; Uochi T; Akinaga S; Aoki N
    J Control Release; 2006 Aug; 114(2):268-75. PubMed ID: 16860428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opsonized erythrocyte ghosts for liver-targeted delivery of antisense oligodeoxynucleotides.
    Kim SH; Kim EJ; Hou JH; Kim JM; Choi HG; Shim CK; Oh YK
    Biomaterials; 2009 Feb; 30(5):959-67. PubMed ID: 19027156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages.
    Oishi M; Nagatsugi F; Sasaki S; Nagasaki Y; Kataoka K
    Chembiochem; 2005 Apr; 6(4):718-25. PubMed ID: 15756696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of EGFR antisense oligodeoxynucleotide on human hepatoma cell line.
    Gong ZB; Liu JM; Li YM
    Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):433-6. PubMed ID: 16109531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.
    Paulos CM; Reddy JA; Leamon CP; Turk MJ; Low PS
    Mol Pharmacol; 2004 Dec; 66(6):1406-14. PubMed ID: 15371560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of a hematoporphyrin derivative in a folate receptor-targeted solid-lipid nanoparticle formulation.
    Stevens PJ; Sekido M; Lee RJ
    Anticancer Res; 2004; 24(1):161-5. PubMed ID: 15015592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-selective drug delivery via folate receptor-targeted liposomes.
    Pan X; Lee RJ
    Expert Opin Drug Deliv; 2004 Nov; 1(1):7-17. PubMed ID: 16296717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.
    Lu Y; Wu J; Wu J; Gonit M; Yang X; Lee A; Xiang G; Li H; Liu S; Marcucci G; Ratnam M; Lee RJ
    Mol Pharm; 2007; 4(5):707-12. PubMed ID: 17708654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine).
    Hwa Kim S; Hoon Jeong J; Chul Cho K; Wan Kim S; Gwan Park T
    J Control Release; 2005 May; 104(1):223-32. PubMed ID: 15866348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.